Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
Milagritos D. Tapia(University of Maryland, Baltimore), Abena Kunadu Yawson, Seth Owusu‐Agyei(Kintampo Health Research Centre), Iris De Ryck(GlaxoSmithKline (Belgium)), Erik Jongert, Marcelo B. Sztein(University of Maryland, Baltimore), Wayne Hogrefe(Cypress College), B Ndiaye(Hôpital Aristide Le Dantec), Akindiran Akintunde, Nick Opoku, Senate Amusu, Thompson Kinge(Bamenda University of Science and Technology), Stephen Oguche(University of Jos), Abdi Naficy(IQVIA (France)), Owusu Boahen, Marguerite Koutsoukos(GlaxoSmithKline (Belgium)), Irma Eneida Almeida Dos Santos, Kwaku Poku Asante(Kintampo Health Research Centre), Myron M. Levine(University of Maryland, Baltimore), Stephan Günther(Bernhard Nocht Institute for Tropical Medicine), Julie A. Ake(Walter Reed Army Institute of Research), D Coly, Fadima Cheick Haidara(Centre Pour le Développement des Vaccins-Mali), Samba O. Sow(Centre Pour le Développement des Vaccins-Mali), Guy Vernet(Université de Reims Champagne-Ardenne), Jean Joël Bigna(Centre Pasteur du Cameroun), Cheikh Ndour(Cheikh Anta Diop University), François Roman(GlaxoSmithKline (Belgium)), Afoke Kokogho, Patricia Bourguignon(GlaxoSmithKline (Belgium)), Leo Ayuk, David Dosoo(Kintampo Health Research Centre), Melanie Ekedi, Seyram Kaali(Kintampo Health Research Centre), Mathurin Cyrille Tejiokem(Centre Pasteur du Cameroun), Muriel Debois(GlaxoSmithKline (Belgium)), Souleymane Mboup(Institute of Health Research, Epidemiological Surveillance and Training), Makhtar Camara, W R Ballou(GlaxoSmithKline (Belgium)), Khardiata Diallo Mbaye(Cheikh Anta Diop University), Awa Traoré(Centre Pour le Développement des Vaccins-Mali), Fatima Sall, Aliou Thiongane(Cheikh Anta Diop University), Catherine Bilong, Moussa Seydi, Kwadwo Koram(University of Ghana), Simon Pitmang, Babajide Keshinro(Janssen (Netherlands))
Cited by 76
Related Papers
Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome
|New England Journal of Medicine|2003|4.8k
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
|Science|2003|2.6k
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451